Emerging regulators of vascular smoothmuscle cell function in the development and progression of atherosclerosis

Cardiovascular Research

Volumn 103, Issue 4, 2014, Pages 452-460

  Johnson, Jason Lee ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Atherosclerosis; Calcification; Foam cell formation; Matrix metalloproteinases; Migration; Vascular smooth muscle cells

Indexed keywords

BETA CATENIN; GALECTIN 3; LIPOPROTEIN; WNT PROTEIN; MATRIX METALLOPROTEINASE;

ARTERY CALCIFICATION; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL WALL; CELL FUNCTION; CELL INTERACTION; CELL MIGRATION; DISEASE COURSE; FOAM CELL; HUMAN; NONHUMAN; PRIORITY JOURNAL; REVIEW; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WNT SIGNALING PATHWAY; ATHEROGENESIS; BLOOD VESSEL CALCIFICATION; CELL TRANSFORMATION; EXTRACELLULAR MATRIX; HEMODYNAMICS; PATHOGENESIS; VASCULAR DISEASE; ANIMAL; CARDIOVASCULAR FUNCTION; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL;

ANIMALS; ATHEROSCLEROSIS; CARDIOVASCULAR PHYSIOLOGICAL PHENOMENA; DISEASE PROGRESSION; HUMANS; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PLAQUE, ATHEROSCLEROTIC;

EID: 84907370419     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvu171     Document Type: Review

References (107)

1. Falk E, Nakano M, Bentzon JF, Finn AV, Virmani R. Update on acute coronary syndromes: the pathologists' view. Eur Heart J 2013;34: 719-728.
2. Stary H. The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life. Eur Heart J 1990;11(Suppl. E): 3-19.
3. Kolodgie FD, BurkeAP, Nakazawa G, Virmani R. Is pathologic intimal thickening the key to understanding early plaque progression in human atherosclerotic disease? Arterioscler Thromb Vasc Biol 2007;27: 986-989.
4. Van der Laan PA, Reardon CA, Getz GS. Site specificity of atherosclerosis. Arterioscler Thromb Vasc Biol 2004;24: 12-22.
5. Förstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J 2012;33: 829-837.
6. Davignon J, Ganz P. Role of Endothelial Dysfunction in Atherosclerosis. Circulation 2004; 109: III-27-III-32.
7. Aicher A, Heeschen C, Mildner-Rihm C, Urbich C, Ihling C, Technau-Ihling K, Zeiher AM, Dimmeler S. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 2003;9: 1370-1376.
8. Akool E-S, Kleinert H, Hamada FMA, Abdelwahab MH, Förstermann U, Pfeilschifter J, EberhardtW. Nitric oxide increases the decay of matrix metalloproteinase 9mRNAby inhibiting the expression of mRNA-stabilizing factor HuR. Mol Cell Biol 2003;23: 4901-4916.
9. Jeremy JY, Rowe D, Emsley AM, Newby AC. Nitric oxide and the proliferation of vascular smooth muscle cells. Cardiovasc Res 1999;43: 580-594.
10. Sarkar R, Meinberg EG, Stanley JC, Gordon D, ClintonWebb R. Nitric oxide reversibly inhibits the migration of cultured vascular smooth muscle cells. Circ Res 1996;78: 225-230.
11. Virmani R, Kolodgie FD, BurkeAP, Farb A, Schwartz SM. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000;20: 1262-1275.
12. Johnson JL. Matrix metalloproteinases: influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 2007;5: 265-282.
13. Johnson JL, George SJ, NewbyAC, Jackson CL. Divergent effects of matrix metalloproteinases -3, -7, -9 and -12 on atherosclerotic plaque stability in mouse brachiocephalic arteries. Proc Natl Acad Sci USA 2005;102: 15575-15580.
14. Johnson JL, Dwivedi A, Somerville M, George SJ, Newby AC. Matrix metalloproteinase (MMP)-3 activatesMMP-9 mediated vascular smooth muscle cell migration and neointima formation in mice. Arterioscler Thromb Vasc Biol 2011;31: e35-e44.
15. ChoA, Reidy MA. Matrix metalloproteinase-9 is necessary for the regulation of smooth muscle cell replication and migration after arterial injury. Circ Res 2002;91: 845-851.
16. Luttun A, Lutgens E, Manderveld A, Maris K, Collen D, Carmeliet P, Moons L. Loss of matrix metalloproteinase-9 or matrix metalloproteinase-12 protects apolipoprotein E-deficient mice against atherosclerotic media destruction but differentially affects plaque growth. Circulation 2004;109: 1408-1414.
17. Choi ET, Collins ET, Marine LA, Uberti MG, Uchida H, Leidenfrost JE, Khan MF, Boc KP, Abendschein DR, Parks WC. Matrix metalloproteinase-9 modulation by resident arterial cells is responsible for injury-induced accelerated atherosclerotic plaque development in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2005;25: 1020-1025.
18. Williams H, Johnson JL, Jackson CL, White SJ, George SJ. MMP-7 mediates cleavage of N-cadherin and promotes smooth muscle cell apoptosis. Cardiovasc Res 2010;87: 137-146.
19. Dwivedi A, Slater SC, George SJ. MMP-9 and -12 cause N-cadherin shedding and thereby {beta}-catenin signalling and vascular smooth muscle cell proliferation. Cardiovasc Res 2009;81: 178-186.
20. Lyon CA, Johnson JL, Williams H, Sala-NewbyGB, George SJ. Soluble N-cadherin overexpression reduces features of atherosclerotic plaque instability. Arterioscler Thromb Vasc Biol 2009;29: 195-201.
21. Jagadeesha DK, Takapoo M, Banfi B, Bhalla RC, Miller FJ Jr. Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. Cardiovasc Res 2012;93: 406-413.
22. Lee JH, Joo JH, Kim J, Lim HJ, Kim S, Curtiss L, Seong JK, Cui W, Yabe-Nishimura C, Bae YS. Interaction of NADPH oxidase 1 with Toll-like receptor 2 induces migration of smooth muscle cells. Cardiovasc Res 2013;99: 483-493.
23. Disanza A, Steffen A, Hertzog M, Frittoli E, Rottner K, Scita G. Actin polymerization machinery: the finish line of signaling networks, the starting point of cellularmovement. Cell Mol Life Sci 2005;62: 955-970.
24. Hall A, Nobes CD. Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton. Phil Trans R Soc B 2000;355: 965-970.
25. Defilippi P, Di Stefano P, Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol 2006;16: 257-263.
26. Pellet-Many C, Frankel P, Evans IM, Herzog B, Junemann-Ramirez M, Zachary IC. Neuropilin-1 mediates PDGF stimulation of vascular smooth muscle cell migration and signalling via p130Cas. Biochem J 2011;435: 609-618.
27. Jope RS, Song L, Grimes CA, Zhang L. Oxidative stress oppositely modulates protein tyrosine phosphorylation stimulated by muscarinic G protein-coupled and epidermal growth factor receptors. J Neurosci Res 1999;55: 329-340.
28. Nakamoto T, Yamagata T, Sakai R, Ogawa S, Honda H, Ueno H, Hirano N, Yazaki Y, Hirai H. CIZ, a zinc finger protein that interacts with p130(cas) and activates the expression of matrix metalloproteinases. Mol Cell Biol 2000;20: 1649-1658.
29. Wang Y, McNiven MA. Invasive matrix degradation at focal adhesions occurs via protease recruitment by a FAK-p130Cas complex. J Cell Biol 2012;196: 375-385.
30. Wang Q, Huang Z, Xue H, Jin C, Ju X-L, Han J-DJ, Chen Y-G. MicroRNA miR-24 inhibits erythropoiesis by targeting activin type I receptor ALK4. Blood 2008;111: 588-595.
31. Latonen L, Jarvinen PM, Laiho M. Cytoskeleton-interacting LIM-domain protein CRP1 suppresses cell proliferation and protects from stress-induced cell death. Exp Cell Res 2008;314: 738-747.
32. Wei J, Gorman TE, Liu XL, Ith B, Tseng A, Chen ZP, Simon DI, Layne MD, Yet SF. Increased neointima formation in cysteine-rich protein 2-deficient mice in response to vascular injury. Circ Res 2005;97: 1323-1331.
33. Zhang T, Zhuang SH, Casteel DE, Looney DJ, Boss GR, Pilz RB.Acysteine-rich LIM-only protein mediates regulation of smooth muscle-specific gene expression by cGMP-dependent protein kinase. J Biol Chem 2007;282: 33367-33380.
34. Lilly B, Clark KA, Yoshigi M, Pronovost S, Wu ML, Periasamy M, Chi M, Paul RJ, Yet SF, Beckerle MC. Loss of the serum response factor cofactor, cysteine-rich protein 1, attenuates neointima formation in the mouse. Arterioscler Thromb Vasc Biol 2010;30: 694-U112.
35. Chen CH, Wu ML, Lee YC, Layne MD, Yet SF. Intronic CArG box regulates cysteine-rich protein 2 expression in the adult but not in developing vasculature. Arterioscler Thromb Vasc Biol 2010;30: 835-U461.
36. Herrmann J, Borkham-Kamphorst E, Haas U, Van de Leur E, Fraga MF, Esteller M, Gressner AM, Weiskirchen R. The expression of CSRP2 encoding the LIM domain protein CRP2 is mediated by TGF-beta in smooth muscle and hepatic stellate cells. Biochem Bioph Res Co 2006;345: 1526-1535.
37. Lin DW, Chang IC, Tseng A, Wu ML, Chen CH, Patenaude CA, Layne MD, Yet SF. Transforming growth factor beta up-regulates cysteine-rich protein 2 in vascular smooth muscle cells via activating transcription factor 2. J Biol Chem 2008;283: 15003-15014.
38. Kihara T, Shinohara S, Fujikawa R, Sugimoto Y, Murata M, Miyake J. Regulation of cysteine-rich protein 2 localization by the development of actin fibers during smooth muscle cell differentiation. Biochem Bioph Res Co 2011;411: 96-101.
39. Chen CH, Ho YC, Ho HH, Chang IC, Kirsch KH, Chuang YJ, Layne MD, Yet SF. Cysteine-rich protein 2 alters p130Cas localization and inhibits vascular smooth muscle cell migration. Cardiovasc Res 2013;100: 461-471.
40. Lyon CA, Koutsouki E, Aguilera CM, BlaschukOW, George SJ. Inhibition of N-cadherin retards smooth muscle cell migration and intimal thickening via induction of apoptosis. J Vasc Surg 2010;52: 1301-1309.
41. George SJ, Wan S, Hu J, MacDonald R, Johnson JL, Baker AH. Sustained reduction of vein graft neointima formation by ex vivo TIMP-3 gene therapy. Circulation 2011;124: S135-S142.
42. Johnson JL, Devel L, Czarny B, George SJ, Jackson CL, Rogakos V, Beau F, Yiotakis A, Newby AC, Dive V. A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice. Arterioscler Thromb Vasc Biol 2011;31: 528-535.
43. Quillard T, Tesmenitsky Y, Croce K, Travers R, Shvartz E, Koskinas KC, Sukhova GK, Aikawa E, Aikawa M, Libby P. Selective inhibition of matrix metalloproteinase-13 increases collagen content of established mouse atherosclerosis. Arterioscler Thromb Vasc Biol 2011;31: 2464-2472.
44. Allahverdian S, Pannu PS, Francis GA. Contribution of monocyte-derived macrophages and smooth muscle cells to arterial foam cell formation. Cardiovasc Res 2012;95: 165-172.
45. Tabas I, Li YQ, Brocia RW, Xu SW, Swenson TL, Williams KJ. Lipoprotein-lipase and sphingomyelinase synergistically enhance the association of atherogenic lipoproteins with smooth-muscle cells and extracellular-matrix - a possible mechanism for low-density-lipoprotein and lipoprotein(a) retention and macrophage foam cellformation. J Biol Chem 1993;268: 20419-20432.
46. Lacolley P, Regnault V, Nicoletti A, Li Z, Michel J-B. The vascular smooth muscle cell in arterial pathology: a cell that can take on multiple roles. Cardiovasc Res 2012;95: 194-204.
47. Choi HY, Rahmani M, Wong BW, Allahverdian S, McManus BM, Pickering JG, Chan T, Francis GA. ATP-binding cassette transporter a1 expression and apolipoprotein a-i binding are impaired in intima-type arterial smooth muscle cells. Circulation 2009; 119: 3223-U3129.
48. Pasterkamp G. Methods of accelerated atherosclerosis in diabetic patients. Heart 2013; 99: 743-749.
49. Xue J-H, Yuan Z, Wu Y, Liu Y, Zhao Y, Zhang W-P, Tian Y-L, Liu W-M, Liu Y, Kishimoto C. High glucose promotes intracellular lipid accumulation in vascular smooth muscle cells by impairing cholesterol influx and efflux balance. Cardiovasc Res 2010;86: 141-150.
50. Ma KL, Liu J, Wang CX, Ni J, Zhang Y, Wu Y, Lv LL, Ruan XZ, Liu BC. Activation of mTOR modulates SREBP-2 to induce foam cell formation through increased retinoblastoma protein phosphorylation. Cardiovasc Res 2013;100: 450-460.
51. Lipskaia L, Pourci M-L, Deloménie C, Combettes L, Goudounèche D, Paul J-L, Capiod T, Lompré A-M. Phosphatidylinositol 3-kinase and calcium-activated transcription pathways are required for VLDL-induced smooth muscle cell proliferation. Circ Res 2003;92: 1115-1122.
52. Van Assche T, Fransen P, Guns PJ, Herman AG, Bult H. Altered Ca2+ handling of smooth muscle cells in aorta of apolipoprotein E-deficient mice before development of atherosclerotic lesions. Cell Calcium 2007;41: 295-302.
53. Ewart M-A, Kennedy S, MacMillan D, Raja ALN, Watt IM, Currie S. Altered vascular smooth muscle function in the ApoE knockout mouse during the progression of atherosclerosis. Atherosclerosis 2014;234: 154-161.
54. Muñoz E, Hernández-Morales M, Sobradillo D, Rocher A, Núñez L, Villalobos C. Intracellular Ca2+ remodeling during the phenotypic journey of human coronary smooth muscle cells. Cell Calcium 2013;54: 375-385.
55. Tong X, Hou X, Jourd'heuil D, Weisbrod RM, Cohen RA. Upregulation of Nox4 by TGFb1 oxidizes SERCA and inhibits NO in arterial smooth muscle of the prediabetic Zucker rat. Circ Res 2010;107: 975-983.
56. Lipskaia L, del Monte F, Capiod T, Yacoubi S, Hadri L, Hours M, Hajjar RJ, Lompré A-M. Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat. Circ Res 2005;97: 488-495.
57. Lipskaia L, Bobe R, Chen J, Turnbull IC, Lopez JJ, Merlet E, Jeong D, Karakikes I, Ross AS, Liang L, Mougenot N, Atassi F, Lompré A-M, TarzamiST, Kovacic JC, Kranias E, Hajjar RJ, Hadri L. Synergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca2+-ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cells. Circulation 2014;129: 773-785.
58. Argmann CA, Sawyez CG, Li SH, Nong ZX, Hegele RA, Pickering JG, HuffMW. Human smooth muscle cell subpopulations differentially accumulate cholesteryl ester when exposed to native and oxidized lipoproteins. Arterioscler Thromb Vasc Biol 2004;24: 1290-1296.
59. Rong JX, Shapiro M, Trogan E, Fisher EA. Transdifferentiation of mouse aortic smooth muscle cells to a macrophage-like state after cholesterol loading. PNAS 2003;100: 13531-13536.
60. Weinert S, Poitz DM, Auffermann-Gretzinger S, Eger L, Herold J, Medunjanin S, Schmeisser A, Strasser RH, Braun-Dullaeus RC. The lysosomal transfer of LDL/cholesterol from macrophages into vascular smooth muscle cells induces their phenotypic alteration. Cardiovasc Res 2013;97: 544-552.
61. Yu HX, Clarke MCH, Figg N, Littlewood TD, Bennett MR. Smooth muscle cell apoptosis promotes vessel remodeling and repair via activation of cell migration, proliferation, and collagen synthesis. Arterioscler Thromb Vasc Biol 2011;31: 2402-U2127.
62. Schaub FJ, Han DKM, Liles WC, Adams LD, Coats SA, Ramachandran RK, Seifert RA, Schwartz SM, Bowen-Pope DF. Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells. Nat Med 2000;6: 706-796.
63. Moehle CW, Bhamidipati CM, Alexander MR, Mehta GS, Irvine JN, Salmon M, Upchurch GR Jr, Kron IL, Owens GK, Ailawadi G. Bone marrow-derived MCP1 required for experimental aortic aneurysm formation and smooth muscle phenotypic modulation. J Thoracic Cardiovasc Surg 2011;142: 1567-1574.
64. Halvorsen B, Dahl TB, Smedbakken LM, Singh A, Michelsen AE, Skjelland M, Krohg-Sørensen K, Russell D, Höpken UE, Lipp M, Damås JK, Holm S, Yndestad A, Biessen EA, Aukrust P. Increased levels of CCR7 ligands in carotid atherosclerosis: different effects in macrophages and smooth muscle cells. Cardiovasc Res 2014;102: 148-156.
65. Clarke MCH, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, Bennett MR. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 2008;102: 1529-1538.
66. Van Vré EA, Ait-Oufella H, Tedgui A, Mallat Z. Apoptotic cell death and efferocytosis in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32: 887-893.
67. Clarke MCH, Talib S, Figg NL, Bennett MR. Vascular smooth muscle cell apoptosis induces interleukin-1-directed inflammation: effects of hyperlipidemia-mediated inhibition of phagocytosis. Circ Res 2010;106: 363-372.
68. Fukumoto Y, Shimokawa H, Ito A, Kadokami T, Yonemitsu Y, Aikawa M, Owada MK, Egashira K, Sueishi K, Nagai R, Yazaki Y, Takeshita A. Inflammatory cytokines cause coronary arteriosclerosis-like changes and alterations in the smooth-muscle phenotypes in pigs. J Cardiovasc Pharmacol 1997;29: 222-231.
69. Bhaskar V, Yin J, Mirza AM, Phan D, Vanegas S, Issafras H, Michelson K, Hunter JJ, Kantak SS. Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice. Atherosclerosis 2011;216: 313-320.
70. Alexander MR, Moehle CW, Johnson JL, Yang Z, Lee JK, Jackson CL, Owens GK. Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice. J Clin Invest 2012;122: 70-79.
71. Alexander MR, Murgai M, MoehleCW, Owens GK. Interleukin-1b modulates smooth muscle cell phenotype to a distinct inflammatory state relative to PDGF-DD via NF-kB-dependent mechanisms. Physiol Genomics 2012;44: 417-429.
72. Kirii H, Niwa T, Yamada Y, Wada H, Saito K, Iwakura Y, Asano M, Moriwaki H, Seishima M. Lack of interleukin-1B decreases the severity of atherosclerosis in ApoEdeficient mice. Arterioscler Thromb Vasc Biol 2003;23: 656-660.
73. Kamari Y, Shaish A, Shemesh S, Vax E, Grosskopf I, Dotan S, White M, Voronov E, Dinarello CA, Apte RN, Harats D. Reduced atherosclerosis and inflammatory cytokines in apolipoprotein-E-deficient mice lacking bone marrow-derived interleukin-1a. Biochem Biophys Res Commun 2011;405: 197-203.
74. Ridker PM, Howard CP, Walter V, Everett B, Libby P, Hensen J, Thuren T. Effects of interleukin-1b inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012;126: 2739-2748.
75. Gomez D, Owens GK. Smooth muscle cell phenotypic switching in atherosclerosis. Cardiovasc Res 2012;95: 156-194.
76. Tang Z, Wang A, Yuan F, Yan Z, Liu B, Chu JS, Helms JA, Li S. Differentiation of multipotent vascular stem cells contributes to vascular diseases. Nat Commun 2012;3: 875.
77. Nguyen AT, Gomez D, Bell RD, Campbell JH, Clowes AW, Gabbiani G, Giachelli CM, Parmacek MS, Raines EW, Rusch NJ, Speer MY, Sturek M, Thyberg J, Towler DA, Weiser-Evans MC, Yan C, Miano JM, Owens GK. Smooth Muscle Cell Plasticity: Fact or Fiction? Circ Res 2013;112: 17-22.
78. Beckman JA, Ganz J, Creager MA, Ganz P, Kinlay S. Relationship of clinical presentation and calcification of culprit coronary artery stenoses. Arterioscler Thromb Vasc Biol 2001; 21: 1618-1622.
79. Ehara S, Kobayashi Y, Yoshiyama M, Shimada K, Shimada Y, Fukuda D, Nakamura Y, Yamashita H, Yamagishi H, Takeuchi K, Naruko T, Haze K, Becker AE, Yoshikawa J, Ueda M. Spotty calcification typifies the culprit plaque in patients with acute myocardial infarction - An intravascular ultrasound study. Circulation 2004;110: 3424-3429.
80. Pflederer T, Marwan M, Schepis T, Ropers D, Seltmann M, Muschiol G, Daniel WG, Achenbach S. Characterization of culprit lesions in acute coronary syndromes using coronary dual-source CT angiography. Atherosclerosis 2010;211: 437-444.
81. NaikV, Leaf EM, Hu JH, Yang H-Y, Nguyen NB, Giachelli CM, SpeerMY. Sources of cells that contribute to atherosclerotic intimal calcification: an in vivo genetic fate mapping study. Cardiovasc Res 2012;94: 545-554.
82. Di Bartolo BA, Schoppet M, Mattar MZ, Rachner TD, Shanahan CM, Kavurma MM. Calcium and osteoprotegerin regulate IGF1R expression to inhibit vascular calcification. Cardiovasc Res 2011;91: 537-545.
83. Nishio E, Arimura S, Watanabe Y. Oxidised LDL induces apoptosis in cultured smooth muscle cells: a possible role for 7-ketocholesterol. Biochem Biophys Res Comm 1996; 223: 413-418.
84. Goettsch C, Rauner M, Hamann C, Sinningen K, Hempel U, Bornstein S, Hofbauer L. Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells. Diabetologia 2011;54: 2690-2701.
85. Sun Y, Byon CH, Yuan KY, Chen JF, Mao X, Heath JM, Javed A, Zhang K, Anderson PG, Chen YB. Smooth muscle cell-specific runx2 deficiency inhibits vascular calcification. Circ Res 2012;111: 543-U230.
86. ZeadinMG, ButcherMK, Shaughnessy SG, WerstuckGH. Leptin promotes osteoblast differentiation andmineralization of primary cultures of vascular smoothmuscle cells by inhibiting glycogen synthase kinase (GSK)-3 beta. Biochem Bioph Res Co 2012;425: 924-930.
87. Woldt E, Terrand J, Mlih M, Matz RL, Bruban V, Coudane F, Foppolo S, El Asmar Z, Chollet ME, Ninio E, Bednarczyk A, Thierse D, Schaeffer C, Van Dorsselaer A, Boudier C, Wahli W, Chambon P, Metzger D, Herz J, Boucher P. The nuclear hormone receptor PPAR gamma counteracts vascular calcification by inhibiting Wnt5a signalling in vascular smooth muscle cells. Nature Commun 2012;3: 1077.
88. Mill C, George SJ. Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. Cardiovasc Res 2012;95: 233-240.
89. Sasaki T, Nakamura K, Sasada K, Okada S, Cheng XW, Suzuki T, Murohara T, Sato K, Kuzuya M. Matrix metalloproteinase-2 deficiency impairs aortic atherosclerotic calcification in ApoE-deficient mice. Atherosclerosis 2013;227: 43-50.
90. Dabelic S, Supraha S, Dumic J. Galectin-3 in macrophage-like cells exposed to immunomodulatory drugs. BBA-Gen Subjects 2006;1760: 701-709.
91. Nangia-Makker P, Raz T, Tait L, Hogan V, Fridman R, Raz A. Galectin-3 cleavage: a novel surrogate marker for matrix metalloproteinase activity in growing breast cancers. Cancer Res 2007;67: 11760-11768.
92. Papaspyridonos M, McNeill E, de Bono JP, Smith A, Burnand KG, Channon KM, Greaves DR. Galectin-3 is an amplifier of inflammation in atherosclerotic plaque progression through macrophage activation and monocyte chemoattraction. Arterioscler Thromb Vasc Biol 2008;28: 433-440.
93. Nachtigal M, Ghaffar A, Mayer EP. Galectin-3 gene inactivation reduces atherosclerotic lesions and adventitial inflammation in ApoE-deficient mice. Am J Pathol 2008;172: 247-255.
94. MacKinnon AC, Liu XJ, Hadoke PWF, Miller MR, Newby DE, Sethi T. Inhibition of galectin-3 reduces atherosclerosis in apolipoprotein E-deficient mice. Glycobiology 2013;23: 654-663.
95. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, Taurino M, Serino M, Marano G, Federici M, Pricci F, Pugliese G. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009;29: 831-U143.
96. ZhuWQ, Sano H, Nagai R, Fukuhara K, Miyazaki A, Horiuchi S. The role of galectin-3 in endocytosis of advanced glycation end products and modified low density lipoproteins. Biochem Bioph Res Co 2001;280: 1183-1188.
97. Seki N, Hashimoto N, Sano H, Horiuchi S, Yagui K, Makino H, Saito Y. Mechanisms involved in the stimulatory effect of advanced glycation end products on growth of rat aortic smooth muscle cells. Metabolism 2003;52: 1558-1563.
98. Menini S, Iacobini C, Ricci C, Fantauzzi CB, Salvi L, Pesce CM, Relucenti M, Familiari G, Taurino M, Pugliese G. The galectin-3/RAGE dyad modulates vascular osteogenesis in atherosclerosis. Cardiovasc Res 2013;100: 472-480.
99. Iacobini C, Menini S, Ricci C, Scipioni A, Sansoni V, Cordone S, Taurino M, Serino M, Marano G, Federici M, Pricci F, Pugliese G. Accelerated lipid-induced atherogenesis in galectin-3-deficient mice: role of lipoxidation via receptor-mediated mechanisms. Arterioscler Thromb Vasc Biol 2009;29: 831-836.
100. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A. Galectin-3, a novel binding partner of beta-catenin. Cancer Res 2004;64: 6363-6367.
101. Shimura T, Takenaka Y, Fukurnori T, Tsutsumi S, Okada K, Hogan V, Kikuchi A, Kuwano H, Raz A. Implication of galectin-3 in Wnt signaling. Cancer Res 2005;65: 3535-3537.
102. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, Hung M-C, Bresalier RS. Galectin-3 mediates nuclear {beta}-catenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3{beta} activity. Cancer Res 2009;69: 1343-1349.
103. Sage AP, Tintut Y, Demer LL. Regulatory mechanisms in vascular calcification. Nat Rev Cardiol 2010;7: 528-536.
104. Bea F, Blessing E, Bennett B, Levitz M, Wallace EP, Rosenfeld ME. Simvastatin promotes atherosclerotic plaque stability in ApoE-deficient mice independently of lipid lowering. Arterioscler Thromb Vasc Biol 2002;22: 1832-1837.
105. Nakazato R, Gransar H, Berman DS, Cheng VY, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ, Cademartiri F, Callister TQ, Chang H-J, Cury RC, Chinnaiyan K, Chow BJW, Delago A, Hadamitzky M, Hausleiter J, Kaufmann P, Maffei E, Raff G, Shaw LJ, Villines TC, Dunning A, Feuchtner G, Kim Y-J, Leipsic J, Min JK. Statins use and coronary artery plaque composition: results from the international multicenter CONFIRM registry. Atherosclerosis 2012;225: 148-153.
106. Guzman RJ. Clinical, cellular, and molecular aspects of arterial calcification. J Vasc Surg 2007;45: A57-A63.
107. Axisa B, Loftus IM, Naylor AR, Goodall S, Jones L, Bell PRF, ThompsonMM. Prospective, randomized, double-blind trial investigating the effect of doxycycline on matrix metalloproteinase expression within atherosclerotic carotid plaques. Stroke 2002;33: 2858-2864.